Back to resultsA Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant
Primary Purpose
Melanoma
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
gp100 human melanoma peptide
Sponsored by
About this trial
This is an interventional treatment trial for Melanoma focused on measuring Cancer, Immunotherapy
Eligibility Criteria
DISEASE CHARACTERISTICS: Metastatic melanoma that is HLA-A2 positive. No primary melanoma of ocular or mucosal origin. Measurable or resected metastatic disease required. PRIOR/CONCURRENT THERAPY: BIOLOGIC THERAPY: No prior (greater than 30 days) or concurrent Biologic Therapy. CHEMOTHERAPY: No prior (greater than 30 days) or concurrent chemotherapy. ENDOCRINE THERAPY: No prior (greater than 30 days) or concurrent hormone therapy. No requirement for steroids. RADIOTHERAPY: No prior (greater than 30 days) or concurrent radiotherapy. SURGERY: Not specified. PATIENT CHARACTERISTICS: Age: 18 and over. Performance Status: ECOG 0 or 1. Life Expectancy: More than 3 months. HEMATOPOIETIC: No coagulation disorder. HEPATIC: Bilirubin no greater than 2.0 mg/dL. No Hepatitis BsAg antibody. RENAL: Creatinine no greater than 2.0 mg/dL. CARDIOVASCULAR: No major cardiovascular illness. PULMONARY: No major respiratory illness. OTHER: No previous allergic reaction to incomplete Freund's adjuvant. HIV negative. No active systemic infection. Not pregnant or lactating.
Sites / Locations
- National Cancer Institute (NCI)
Outcomes
Primary Outcome Measures
Secondary Outcome Measures
Full Information
NCT ID
NCT00001439
First Posted
November 3, 1999
Last Updated
March 3, 2008
Sponsor
National Cancer Institute (NCI)
1. Study Identification
Unique Protocol Identification Number
NCT00001439
Brief Title
A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant
Official Title
A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant
Study Type
Interventional
2. Study Status
Record Verification Date
May 1999
Overall Recruitment Status
Completed
Study Start Date
June 1995 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
April 2000 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
National Cancer Institute (NCI)
4. Oversight
5. Study Description
Brief Summary
This is a phase I study of melanoma tumor antigen peptide vaccines. The nine amino acid peptides representing HLA-A2 restricted T cell epitope of the melanoma antigen, gp100 will be administered to patients emulsified in Incomplete Freund's Adjuvant, (IFA). The study is designed to evaluate the toxicity, immunologic effects and potential therapeutic role of repeated doses of gp100 peptide vaccines administered subcutaneously.
Immune reactivity to the gp100 epitope peptides will be monitored in all patients by analysis of melanoma-specific T cell precursor frequency prior to and after immunization.
Detailed Description
This is a phase I study of melanoma tumor antigen peptide vaccines. The nine amino acid peptides representing HLA-A2 restricted T cell epitope of the melanoma antigen, gp100 will be administered to patients emulsified in Incomplete Freund's Adjuvant, (IFA). The study is designed to evaluate the toxicity, immunologic effects and potential therapeutic role of repeated doses of gp100 peptide vaccines administered subcutaneously.
Immune reactivity to the gp100 epitope peptides will be monitored in all patients by analysis of melanoma-specific T cell precursor frequency prior to and after immunization.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Melanoma
Keywords
Cancer, Immunotherapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Enrollment
255 (false)
8. Arms, Groups, and Interventions
Intervention Type
Biological
Intervention Name(s)
gp100 human melanoma peptide
10. Eligibility
Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS:
Metastatic melanoma that is HLA-A2 positive.
No primary melanoma of ocular or mucosal origin.
Measurable or resected metastatic disease required.
PRIOR/CONCURRENT THERAPY:
BIOLOGIC THERAPY: No prior (greater than 30 days) or concurrent Biologic Therapy.
CHEMOTHERAPY: No prior (greater than 30 days) or concurrent chemotherapy.
ENDOCRINE THERAPY: No prior (greater than 30 days) or concurrent hormone therapy.
No requirement for steroids.
RADIOTHERAPY: No prior (greater than 30 days) or concurrent radiotherapy.
SURGERY: Not specified.
PATIENT CHARACTERISTICS:
Age: 18 and over.
Performance Status: ECOG 0 or 1.
Life Expectancy: More than 3 months.
HEMATOPOIETIC: No coagulation disorder.
HEPATIC:
Bilirubin no greater than 2.0 mg/dL.
No Hepatitis BsAg antibody.
RENAL: Creatinine no greater than 2.0 mg/dL.
CARDIOVASCULAR: No major cardiovascular illness.
PULMONARY: No major respiratory illness.
OTHER:
No previous allergic reaction to incomplete Freund's adjuvant.
HIV negative.
No active systemic infection.
Not pregnant or lactating.
Facility Information:
Facility Name
National Cancer Institute (NCI)
City
Bethesda
State/Province
Maryland
ZIP/Postal Code
20892
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
9136454
Citation
Rosenberg SA. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today. 1997 Apr;18(4):175-82. doi: 10.1016/s0167-5699(97)84664-6. No abstract available.
Results Reference
background
PubMed Identifier
8931607
Citation
Rosenberg SA. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst. 1996 Nov 20;88(22):1635-44. doi: 10.1093/jnci/88.22.1635.
Results Reference
background
PubMed Identifier
9500606
Citation
Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998 Mar;4(3):321-7. doi: 10.1038/nm0398-321.
Results Reference
background
Learn more about this trial
A Phase I Study of gp100 Human Melanoma Peptide Vaccine With Incomplete Freund's Adjuvant
We'll reach out to this number within 24 hrs